Business Wire

Data Professionals Waste 50 Percent of Time on Unsuccessful or Repeated Data Efforts, Costing Organizations Millions

Jaa

Alteryx, Inc. (NYSE: AYX), revolutionizing business through data science and analytics, today revealed that data professionals are wasting half of their time each week finding, protecting, or preparing data —costing organizations significant amounts of money. The IDC InfoBrief: The State of Data Discovery and Cataloging, commissioned by Alteryx, is based on a comprehensive survey of 400-plus individuals performing data functions across North America and Europe.

Despite massive growth in data analytics demand globally, this new study shows that there is still much work to be done for organizations to get the most of their data assets and infrastructures, particularly when it comes to data discovery and cataloging. Data professionals are spending more time governing, searching and preparing data than they are on extracting business value. Among the findings:

  • Data professionals spend 60 percent of their time getting to insight, but just 27 percent of that time is spent on actual analysis. Instead, 37 percent of that “getting to insight” time is spent searching for data and 36 percent of that time is spent preparing data.
  • These data workers waste 30 percent of their time—on average 14 hours per week—because they cannot find, protect or prepare data. They waste another 20 percent of their time—10 hours per week—building information assets that already exist. In total, they lose 50 percent of their time every week on unsuccessful activities or repeating efforts.
  • Even though data discovery and integrity is important for business, 30 to 50 percent of organizations say they are not where they want to be.
  • The inefficiencies of data intelligence and knowledge is costing U.S. organizations $1.7M per year for every 100 employees, and European organizations €1.1M per year for every 100 employees.

“It is evident that many professionals are not aware of what resources are available within data assets like data lakes, how to access the data, where it came from, or how to glean trusted insights,” said Langley Eide, Chief Strategy Officer at Alteryx, Inc. “Unless organizations make changes to their infrastructure now, and close the gaps on data discovery, integrity and cataloging, processes will only become more inefficient as data volume and variety continues to grow.”

“Data discovery is important to all aspects of business, from operations efficiency to compliance to risk reduction, revenue growth, and beyond,” said Stewart Bond, Director of Data Integration and Integrity Software Research at IDC. “Knowledge of how, where and why data is used, by whom, and what information already exists will help data professionals refrain from repeating efforts, increase personal productivity and free-up time for more advanced analytics.”

To download the full IDC InfoBrief, please visit www.alteryx.com/idc-data-catalog.

About Alteryx

Revolutionizing business though data science and analytics, Alteryx offers an end-to-end analytics platform which empowers data analysts and scientists alike to break data barriers, deliver insights, and experience the thrill of getting to the answer faster. Organizations all over the world rely on Alteryx daily to deliver actionable insights. For more information visit www.alteryx.com.

Alteryx is a registered trademark of Alteryx, Inc. All other product and brand names may be trademarks or registered trademarks of their respective owners.

Contact information

Media Contact
Alteryx
Lisa Soto
Director of Corporate Communications
Direct: 949-668-1455 | Mobile: 949-351-3734
lsoto@alteryx.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

CES Asia: Innovation at the Speed of 5G15.6.2018 17:59Tiedote

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

AGP Group Announces the Acquisition of Soliver NV in Belgium, Representing a Key Step towards Becoming the Premier Global Leader in Designing and Manufacturing High-Tech Automotive Glazing15.6.2018 12:00Tiedote

AGP, a high-tech specialty glass designer and manufacturer, has announced today the acquisition of Soliver NV, a European automotive glazing manufacturer with over 65 years of solid product and brand reputation. Soliver offers high-quality tempered and laminated glazing for high-end automobiles, as well as windshield solutions for trucks. AGP’s glazing heritage started in Berlin, with the Mannheim family´s first glass company. After 100 years and a clear vision to become a leader in specialty glass, AGP’s core eGlass technologies have responded to the rising demand in electrification, connectivity, shared mobility and autonomous driving, acting as an enabler of future mobility trends. The integration of Soliver into the AGP Group will strengthen the AGP eGlass value proposition and will be a game changer in a fast-evolving industry. “We are very excited to build upon Soliver’s great experience and track-record to take high-tech glazing to the next level, enabling our customer’s product

Rivoli Group announces completion of its new international corporate strategy15.6.2018 10:00Tiedote

Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/ Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire) The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together. "This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said. The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings

PMI’s Latest Clinical Results: Findings Add to Extensive Evidence Package on Risk Reduction15.6.2018 10:00Tiedote

Philip Morris International (PMI) (NYSE:PM) announces today the positive results from a new clinical study on IQOS, the company’s most advanced smoke-free product. The Exposure Response Study (ERS) measured the biological response of people who switch to IQOS for six months compared with continued smoking. The study met its primary objective, demonstrating that after six months, eight measures of biological response (the primary clinical risk endpoints) improved in those who switched to IQOS. PMI’s Scientific Assessment Program has rigorously tested IQOS over more than 7 years and supports that switching to our most advanced smoke-free product is likely to present less risk of harm than continuing to use cigarettes. Numerous aerosol chemistry and physics measurements demonstrate that IQOS aerosol contains an average of 90-95% lower levels of harmful constituents. Our results support that these reduced emissions translate to reduced toxicity in the laboratory and to reduced exposure in

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme